Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CDC’s ACIP supports COVID-19 boosters for all adults

By Brian Buntz | November 22, 2021

CDC COVID-19The Advisory Committee on Immunization Practices (ACIP) at the CDC voted unanimously to allow all fully vaccinated adults to receive a COVID-19 booster at least six months after receiving a primary series.

All 11 members of the panel also voted on Nov. 19 to recommend boosters for adults 50 and older.

Last week, FDA authorized the mRNA vaccines from Pfizer-BioNTech (NYSE:PFE/NSDQ:BNTX) and Moderna (NSDQ:MRNA) boosters for all adults at least six months after completion of a primary series.

Previously, government authorities had recommended boosters for people 65 and older, those who are moderately to severely immunocompromised, and those at high risk of exposure in occupational or residential settings.

Several states aimed to sidestep the federal government’s booster requirements by allowing all fully adults who received an mRNA-based COVID-19 vaccine to obtain a booster, provided at least six months had elapsed before receiving the second vaccine dose.

Guidance is more precise for those who received the single-dose Janssen COVID-19 vaccine. All Janssen vaccine recipients may receive a second dose at least two months after receiving a dose of that vaccine.

ACIP recently recommended a primary vaccination series for children between the ages of 5 and 11.

The American Medical Association applauded the news. In a statement, President Dr. Gerald E. Harmon said that the AMA believes “the FDA’s authorization and the ACIP’s recommendations in support of booster doses for all adults will help provide continued protection against COVID-19 as we head into the winter months.”

While praising the move to open up booster eligibility, some physicians criticized the guidance for not encouraging all adults who received mRNA vaccines to receive boosters.

“I don’t get it, based on data from Israel and The Lancet, I don’t understand the ‘should/may’ split,” said Dr. Peter Hotez, dean for the National School of Tropical Medicine at Baylor University, over Twitter. Interpreting the federal guidance as implying that eligible adults 50 or older should obtain a booster while those 18 and older may obtain a dose “just confuses,” he added. “Everyone over 18 should get the booster. Otherwise, we won’t get back to normal.”


Filed Under: Infectious Disease
Tagged With: ACIP, Advisory Committee on Immunization Practices, BioNTech, covid-19, COVID-19 booster, COVID-19 vaccine, COVID-19 vaccines, Moderna, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Vaccines, autism and America: A stress test for public health standards
RSV at IDWeek 2025: Competitive expansion of preventive and therapeutic modalities
Top 25 drugs by sales: 2025 H1
Bipartisan support for vaccines could be a balm for beleaguered vaccine companies
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE